JNJ-17299425

Phase 2Terminated

1 views this week 0 watching💤 Quiet

Interest: 27/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Traumatic Brain Injury

Conditions

Traumatic Brain Injury

Trial Timeline

Aug 1, 2007 → Aug 1, 2008

NCT ID

NCT01814982

About JNJ-17299425

JNJ-17299425 is a phase 2 stage product being developed by Johnson & Johnson for Traumatic Brain Injury. The current trial status is terminated. This product is registered under clinical trial identifier NCT01814982. Target conditions include Traumatic Brain Injury.

What happened to similar drugs?

8 of 17 similar drugs in Traumatic Brain Injury were approved

Approved (8) Terminated (5) Active (5)

✅Galcanezumab-GnlmEli LillyApproved

✅Placebo + sertralineJohnson & JohnsonApproved

✅Adjunctive asenapineMerckApproved

✅AlendronateMerckApproved

✅RivastigmineNovartisApproved

✅ZiprasidonePfizerApproved

✅AbobotulinumtoxinA + Normal salineIpsenApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01814982	Phase 2	Terminated	Aug 1, 2007	Aug 1, 2008	Traumatic Brain Injury

Competing Products

20 competing products in Traumatic Brain Injury

See all competitors

Product	Company	Stage	Hype Score
Duloxetine + Sugar pill	Eli Lilly	Phase 2	27
Neurosteroid enantiomer	Oragenics	Phase 2	32
Celecoxib	Astellas Pharma	Pre-clinical	26
Mupirocin Calcium Cream, 2% + Bactroban® Cream + Cream vehicle of test product	Sun Pharmaceutical	Phase 1	29
Duloxetine hydrochloride	Eli Lilly	Phase 3	36
Galcanezumab-Gnlm	Eli Lilly	Approved	43
SYN117 (nepicastat) + Placebo comparator	Johnson & Johnson	Phase 2	27
Nepicastat + Placebo	Johnson & Johnson	Phase 2	35
Placebo + sertraline	Johnson & Johnson	Approved	35
Quetiapine Fumarate + quetiapine fumarate placebo	AstraZeneca	Phase 3	40
Adjunctive asenapine	Merck	Approved	43
Rizatriptan + Placebo	Merck	Pre-clinical	18
Alendronate	Merck	Approved	39
Iloperidone + Placebo	Novartis	Phase 2	27
AMG 334	Novartis	Phase 2	35
Rivastigmine	Novartis	Phase 3	40
Rivastigmine	Novartis	Approved	43
Balovaptan + Placebo	Roche	Phase 2	35
Erenumab	Amgen	Phase 2	35
Growth Hormone	Novo Nordisk	Phase 2	42